Official Louisiana State Websites use .la.gov 
Secure .gov websites use HTTPS 
Louisiana Department of Health urges caution to prevent Vibrio vulnificus infection
The department is seeing a higher number of Vibrio vulnificus cases and deaths than are typically reported.
LDH News
-
-
Louisiana Medicaid Increased Physician Reimbursement Rates Beginning July 1, 2025
Effective July 1, 2025, Medicaid physician reimbursement rates increased to 85% of the March 2024 Region 99 Medicare rates for applicable services. Reimbursements at or above this threshold will remain the same.
-
Emergency Rule: Consumable Hemp Products
-
Emergency Rule: Regulation of Medical Marijuana
-
Final Rule: Commercial Body Art
-
Final Rule: EMS Professionals
-
Final Rule: Emergency Medical Transportation Services Licensing Standards
-
Hospital Services – Coverage of Gene Therapies for Sickle Cell Disease LAC 50:V.120
Continues the July 1, 2025 Emergency Rule which adopted cell and gene therapy model that provides additional supplemental and federal rebates for gene therapies for sickle cell disease.
-
Nursing Facilities – Reimbursement Methodology LAC 50:VII.Chapter 200
Continues the June 30, 2025 Emergency Rule which amended the provisions governing reimbursement for Nursing Facilities to revise the language and to replace resource utilization group resident classification system with the patient driven payment model.
-
Professional Services Program – Reimbursement Methodology (LAC 50:IX.8305, 8505, 15113, 15133, and XIX.4334)
Adopts a new methodology for Medicaid managed care organization reimbursement and fee-for-service reimbursement rates to better align Medicaid rates to Medicare rates.
-
Refugee Medical Assistance LAC 50:XXXI.Chapter 1
Amends the provisions governing refugee medical assistance (RMA) to shorten the period that assistance is granted through the refugee medical assistance (RMA) program from one year to four months.
-
Hospital Services – Coverage of Gene Therapies for Sickle Cell Disease LAC 50:V.120
Amends the provisions governing inpatient hospital services, to allow reimbursement for gene therapies for sickle cell disease outside the per diem rate and paid based on the actual acquisition cost in order to take advantage of a federal rebate.